Fig. 2: Progression-free survival of MTA and SC treatment lines. | npj Precision Oncology

Fig. 2: Progression-free survival of MTA and SC treatment lines.

From: Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer

Fig. 2

Treatment lines were stratified by administration of molecularly targeted agents (MTAs, blue) and standard chemotherapies (SC, red). Kaplan-Meier analysis by treatment types is shown for all lines of therapy (a), lines administered before precision oncology decision support (DS) (b), and lines administered after precision oncology decision support (c).

Back to article page